JP2022512580A5 - - Google Patents

Info

Publication number
JP2022512580A5
JP2022512580A5 JP2021518066A JP2021518066A JP2022512580A5 JP 2022512580 A5 JP2022512580 A5 JP 2022512580A5 JP 2021518066 A JP2021518066 A JP 2021518066A JP 2021518066 A JP2021518066 A JP 2021518066A JP 2022512580 A5 JP2022512580 A5 JP 2022512580A5
Authority
JP
Japan
Prior art keywords
composition according
biofilm
polypeptide
subject
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021518066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512580A (ja
JP7541513B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/054868 external-priority patent/WO2020073004A1/en
Publication of JP2022512580A publication Critical patent/JP2022512580A/ja
Publication of JP2022512580A5 publication Critical patent/JP2022512580A5/ja
Priority to JP2024078577A priority Critical patent/JP2024105533A/ja
Application granted granted Critical
Publication of JP7541513B2 publication Critical patent/JP7541513B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021518066A 2018-10-05 2019-10-04 細菌バイオフィルムの酵素的破壊のための組成物および方法 Active JP7541513B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024078577A JP2024105533A (ja) 2018-10-05 2024-05-14 細菌バイオフィルムの酵素的破壊のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862742158P 2018-10-05 2018-10-05
US62/742,158 2018-10-05
PCT/US2019/054868 WO2020073004A1 (en) 2018-10-05 2019-10-04 Compositions and methods for enzymatic disruption of bacterial biofilms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024078577A Division JP2024105533A (ja) 2018-10-05 2024-05-14 細菌バイオフィルムの酵素的破壊のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022512580A JP2022512580A (ja) 2022-02-07
JP2022512580A5 true JP2022512580A5 (https=) 2022-09-13
JP7541513B2 JP7541513B2 (ja) 2024-08-28

Family

ID=70054909

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518066A Active JP7541513B2 (ja) 2018-10-05 2019-10-04 細菌バイオフィルムの酵素的破壊のための組成物および方法
JP2024078577A Withdrawn JP2024105533A (ja) 2018-10-05 2024-05-14 細菌バイオフィルムの酵素的破壊のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024078577A Withdrawn JP2024105533A (ja) 2018-10-05 2024-05-14 細菌バイオフィルムの酵素的破壊のための組成物および方法

Country Status (7)

Country Link
US (1) US12161701B2 (https=)
EP (1) EP3861021B1 (https=)
JP (2) JP7541513B2 (https=)
CN (1) CN112771074A (https=)
AU (1) AU2019355194B2 (https=)
CA (1) CA3114925A1 (https=)
WO (1) WO2020073004A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118206617B (zh) * 2024-05-20 2024-07-30 烟台大学 一类能特异性结合霍利迪连接体的多肽探针及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
DE3424893A1 (de) 1984-07-06 1986-02-06 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches silberhalogenidaufzeichnungsmaterial
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2196002T3 (es) 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
ES2230848T3 (es) 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
SI1858920T1 (sl) * 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CN103097399A (zh) 2010-03-29 2013-05-08 南加利福尼亚大学 用于去除生物膜的组合物及方法
US20160194384A1 (en) * 2014-06-12 2016-07-07 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
ES2746971T3 (es) 2013-06-13 2020-03-09 Res Inst Nationwide Childrens Hospital Composiciones y procedimientos para el tratamiento de infecciones por burkholderia
US20170182205A1 (en) * 2015-12-28 2017-06-29 ProclaRx LLC Medical devices with biofilm disruptors
JP7661008B2 (ja) * 2017-01-04 2025-04-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルム関連障害の処置のための抗体断片

Similar Documents

Publication Publication Date Title
JP6420417B2 (ja) バイオフィルムを除去するための組成物および方法
Samson et al. Long-term effects of azithromycin in patients with cystic fibrosis
JP2018534247A (ja) 肺サーファクタントによって阻害される抗生物質の肺サーファクタントの存在下における抗細菌活性を回復／増加させるための溶解素の使用
JP2023519241A5 (https=)
CN102724983A (zh) 雾化左氧氟沙星治疗囊性纤维化的用途
JP2022531929A5 (https=)
JP2017519768A5 (https=)
Keller et al. Surface proteins and pneumolysin of encapsulated and nonencapsulated Streptococcus pneumoniae mediate virulence in a chinchilla model of otitis media
JP2010527960A5 (https=)
Baumann et al. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study
JP2022512580A5 (https=)
Cavel et al. Changes in the epidemiology and clinical features of acute mastoiditis following the introduction of the pneumococcal conjugate vaccine
Cakan et al. S-carboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells
Rahmati et al. Fluticasone nasal spray as an adjunct to Amoxicillin for acute sinusitis in children: a randomized controlled trial
Leophonte et al. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis
Zoumot et al. Respiratory infection in noncystic fibrosis bronchiectasis
Pennington et al. Summary of a workshop on infections in patients with cystic fibrosis
Regan et al. Risk of development of resistance in patients with non-cystic fibrosis bronchiectasis treated with inhaled antibiotics
Mora et al. Efficacy of a topical suspension of bacterial antigens for the management of chronic suppurative otitis media
Ragesh et al. Cavitary lung lesions in a difficult-to-treat asthma patient
Thanavala et al. Role of nontypeable Haemophilus influenzae in otitis media and chronic obstructive pulmonary disease
File Jr Telithromycin new product overview
WO2018121499A1 (zh) 抗结核分枝杆菌(Mycobacterium tuberculosis)及其感染的药物及其应用
Meyer et al. Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease
Koch et al. Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice: evidence from a post-marketing surveillance study of 1467 patients